Clarus’s short-term mission is to develop a unique oral testosterone product that is safe and effective for use in the clinical management of men with testosterone deficiency (medically known as male hypogonadism).

Once Clarus’s oral platform technology has been perfected, other potential applications for use include development of a low-dose testosterone supplement for women and, long-term, potentially an oral male contraceptive product.

Clarus is a privately held biopharmaceutical company whose focus is the development and commercialization of androgen-based prescription drug products for men and women. Clarus’s lead product is OriTex™ – a proprietary oral testosterone product in Phase II development.

In November 2007, Clarus closed a Series C financing round totaling $8 million. Clarus will use the proceeds to support Phase II development of OriTex™, its proprietary oral testosterone product being developed for use in men with low testosterone levels. H. I. G. Ventures led the round and was joined by Thomas, McNerney & Partners – the sole institutional investor in the Series A and B financing rounds. To date, Clarus has secured $15 million in venture funding commitments.